Johnson & Johnson’s Stelara was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn’s disease, according to data from a late stage trial, providing ammunition for a potential expanded approval of the medicine. Stelara, a biotech medicine that blocks inflammation, is approved to treat the skin condition […]

Drug developer Genocea Biosciences Inc said it was suspending the development of a vaccine for pneumonia-causing bacteria after it failed to significantly reduce infection in a mid-stage study. The company’s shares fell 34 percent to $4.75 in premarket trading. Genocea said it was dropping the development of the vaccine, GEN-004, from its near-term plans to […]

Zafgen Inc said the U.S. Food and Drug Administration had put a late-stage trial of its obesity drug on partial hold, two days after the drug developer reported the death of a patient during the study. Zafgen’s stock was down about 24 percent at $15.92 in light premarket trading. Zafgen said it still expects to […]

PTC Therapeutics Inc’s experimental muscle disorder drug failed to meet the main goal in a keenly watched late-stage study, but the company said data from all trials on the drug supported a U.S. marketing application. The company’s stock fell about 16 percent in extended trading on Thursday, before reversing course to notch marginally gains. PTC […]

Drug developer Transition Therapeutics Inc said its experimental drug reduced severe agitation and aggression in Alzheimer’s patients, citing data from a large study. The company said on Thursday that it would use the data to discuss a potential late-stage trial of the drug, ELND005, with the U.S. Food and Drug Administration. The company said in […]

U.S. health regulators declined to approve Pfizer Inc’s oral rheumatoid arthritis drug Xeljanz to treat moderate to severe cases of the scaly skin condition plaque psoriasis, the drugmaker said on Wednesday. Pfizer said it received a so-called complete response letter from the Food and Drug Administration. Such letters typically outline concerns and conditions that must […]

Drug developer Zosano Pharma Corp said a mid-stage study testing its experimental patch to treat low blood sugar met the main goal. The company said the patch, ZP-Glucagon, normalized blood sugar in all the patients who received it. ZP-Glucagon is the lead treatment that Zosano is developing. The company is also developing a therapy for […]

The odds that Merck & Co’s high-stakes cholesterol drug will succeed have dropped dramatically after Eli Lilly and Co said its similar medicine failed to reduce heart attacks and strokes, top U.S. heart doctors said. Lilly on Monday said it was halting a 12,000-patient study of its drug, evacetrapib, an oral medication. In earlier studies, […]

Eli Lilly and Co has stopped a late-stage trial of its closely watched cholesterol treatment after the drug proved ineffective, sending its shares as much as 9 percent lower and hitting the stock of Merck & Co Inc, which is developing a similar medicine. “Today’s news is a negative for Lilly and we anticipate that […]

Quebec City, Canada-based AEterna Zentaris (AEZS) announced today that the company’s Dennis Turpin, senior vice president and chief financial officer, would be stepping down. In addition, AEterna Zentaris is closing its Quebec City office at the end of the year and consolidating functions at its Charleston, S.C. office.   The company focuses on developing and […]